924
Participants
Start Date
May 7, 2023
Primary Completion Date
December 28, 2024
Study Completion Date
March 31, 2026
Low dose Recombinant Herpes Zoster Vaccine (CHO cells)
0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.
High dose Recombinant Herpes Zoster Vaccine (CHO cells)
0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.
Positive control
0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
Placebo
0.5 mL per dose, containing 4.5 mg sodium chloride.
Yanjin Center for Disease Control and Prevention, Xinxiang
Lead Sponsor
Henan Center for Disease Control and Prevention
OTHER_GOV
MAXVAX Biotechnology Limited Liability Company
INDUSTRY